Lew TE, Anderson MA, Lin VS, Handunnetti SM, Came NA., Blombery P, Westerman DA, Wall M, Tam
CS, Roberts AW, Seymour JF. Undetectable peripheral blood MRD should be the goal of venetoclax in
CLL, but attainment plateaus after 24 months. Blood Adv. 2020 Jan 14;4(1):165-173. doi:
10.1182/bloodadvances.2019000864.
Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown
JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA,
Wierda WG, Seymour JF. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
N Engl J Med. 2016 Jan 28;374(4):311-22.
Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L,
Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF. Efficacy of
venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.
Blood. 2019 Jul 11;134(2):111-122.
